Desvenlafaxine: A new antidepressant or just another one?

Chi Un Pae

doi:10.1517/14656560902828351

Desvenlafaxine: A new antidepressant or just another one?

Chi Un Pae

Department of Psychiatry

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Desvenlafaxine (DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a different pharmacokinetic and pharmacodynamic profile to venlafaxine. It was approved in February 2008 by the United States Food and Drug Administration for the treatment of major depressive disorder (MDD) based on a number of randomized, placebo-controlled clinical trials demonstrating efficacy and safety for patients with MDD. Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors. As with all monoamine-based antidepressants, DVS has mixed efficacy results from individual studies, unestablished dosing strategies and limited long-term data, and comparative efficacy/safety with other existing antidepressants should be further investigated. Preliminary evidence also suggests the clinical usefulness of DVS in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms, although only MDD is the approved indication.

Original language	English
Pages (from-to)	875-887
Number of pages	13
Journal	Expert Opinion on Pharmacotherapy
Volume	10
Issue number	5
DOIs	https://doi.org/10.1517/14656560902828351
State	Published - Apr 2009

Bibliographical note

Funding Information:
Pae has received a research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, the Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, the Catholic Medical Center, and the Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker’s bureaus of Glaxo-SmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty, Inc. and Otsuka Korea Pharmaceuticals, Inc.

Funding Information:
This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0). The manufacturer of desvenlafaxine, Wyeth, did not contribute to any part of this work.

Keywords

Antidepressant
Anxiety
Depression
Desvenlafaxine
Menopause
SNRI
Venlafaxine

Access to Document

10.1517/14656560902828351

Cite this

@article{3531c9e415274c2d9e8a6aa7cc8b8b2b,

title = "Desvenlafaxine: A new antidepressant or just another one?",

abstract = "Desvenlafaxine (DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a different pharmacokinetic and pharmacodynamic profile to venlafaxine. It was approved in February 2008 by the United States Food and Drug Administration for the treatment of major depressive disorder (MDD) based on a number of randomized, placebo-controlled clinical trials demonstrating efficacy and safety for patients with MDD. Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors. As with all monoamine-based antidepressants, DVS has mixed efficacy results from individual studies, unestablished dosing strategies and limited long-term data, and comparative efficacy/safety with other existing antidepressants should be further investigated. Preliminary evidence also suggests the clinical usefulness of DVS in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms, although only MDD is the approved indication.",

keywords = "Antidepressant, Anxiety, Depression, Desvenlafaxine, Menopause, SNRI, Venlafaxine",

author = "Pae, \{Chi Un\}",

note = "Funding Information: Pae has received a research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, the Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, the Catholic Medical Center, and the Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker{\textquoteright}s bureaus of Glaxo-SmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty, Inc. and Otsuka Korea Pharmaceuticals, Inc. Funding Information: This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0). The manufacturer of desvenlafaxine, Wyeth, did not contribute to any part of this work.",

year = "2009",

month = apr,

doi = "10.1517/14656560902828351",

language = "English",

volume = "10",

pages = "875--887",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Desvenlafaxine

T2 - A new antidepressant or just another one?

AU - Pae, Chi Un

N1 - Funding Information: Pae has received a research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, the Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, the Catholic Medical Center, and the Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker’s bureaus of Glaxo-SmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty, Inc. and Otsuka Korea Pharmaceuticals, Inc. Funding Information: This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0). The manufacturer of desvenlafaxine, Wyeth, did not contribute to any part of this work.

PY - 2009/4

Y1 - 2009/4

N2 - Desvenlafaxine (DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a different pharmacokinetic and pharmacodynamic profile to venlafaxine. It was approved in February 2008 by the United States Food and Drug Administration for the treatment of major depressive disorder (MDD) based on a number of randomized, placebo-controlled clinical trials demonstrating efficacy and safety for patients with MDD. Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors. As with all monoamine-based antidepressants, DVS has mixed efficacy results from individual studies, unestablished dosing strategies and limited long-term data, and comparative efficacy/safety with other existing antidepressants should be further investigated. Preliminary evidence also suggests the clinical usefulness of DVS in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms, although only MDD is the approved indication.

AB - Desvenlafaxine (DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a different pharmacokinetic and pharmacodynamic profile to venlafaxine. It was approved in February 2008 by the United States Food and Drug Administration for the treatment of major depressive disorder (MDD) based on a number of randomized, placebo-controlled clinical trials demonstrating efficacy and safety for patients with MDD. Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors. As with all monoamine-based antidepressants, DVS has mixed efficacy results from individual studies, unestablished dosing strategies and limited long-term data, and comparative efficacy/safety with other existing antidepressants should be further investigated. Preliminary evidence also suggests the clinical usefulness of DVS in the treatment of vasomotor symptoms of menopause, anxiety symptoms and painful physical symptoms, although only MDD is the approved indication.

KW - Antidepressant

KW - Anxiety

KW - Depression

KW - Desvenlafaxine

KW - Menopause

KW - SNRI

KW - Venlafaxine

UR - https://www.scopus.com/pages/publications/67649624781

U2 - 10.1517/14656560902828351

DO - 10.1517/14656560902828351

M3 - Review article

C2 - 19351235

AN - SCOPUS:67649624781

SN - 1465-6566

VL - 10

SP - 875

EP - 887

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 5

ER -

Desvenlafaxine: A new antidepressant or just another one?

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this